Orchestra BioMed Holdings (OBIO) Capital Expenditures (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Capital Expenditures of $184000.0 for Q1 2026, up 64.29% year-over-year from $112000.0 in Q1 2025, and up 111.49% quarter-over-quarter from $87000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Capital Expenditures (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Capital Expenditures for 5 consecutive years, with $184000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 64.29% year-over-year to $184000.0; the TTM figure through Mar 2026 stood at $241000.0 (down 38.68% YoY), while the FY2025 annual figure was $169000.0, down 41.52% from the prior year.
- Capital Expenditures advanced to $184000.0 in Q1 2026 per OBIO's latest filing, from $87000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $266000.0 in Q2 2022 and bottomed at -$64000.0 in Q3 2025.
- Historically, Capital Expenditures has averaged $77117.6 across 5 years, with a median of $54000.0 in 2022.
- Annual changes were most pronounced in 2024 — Capital Expenditures jumped 3633.33% — and 2025, when it sank 194.12%.
- Orchestra BioMed Holdings' Capital Expenditures stood at $54000.0 in 2022, then slumped by 105.56% to -$3000.0 in 2023, then surged by 3633.33% to $106000.0 in 2024, then declined by 17.92% to $87000.0 in 2025, then soared by 111.49% to $184000.0 in 2026.
- Business Quant data shows OBIO's Capital Expenditures at $184000.0 in Q1 2026, $87000.0 in Q4 2025, and -$64000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 254,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 254,000.00 |
| Mar 31, 2026 | 184,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Sep 30, 2025 | 310,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 112,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Dec 31, 2023 | -3,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 27,000.00 |
| Mar 31, 2023 | 35,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 224,000.00 |
| Jun 30, 2022 | 266,000.00 |
| Mar 31, 2022 | 47,000.00 |